Modern treatment tactics and prophylaxis of bacterial vaginosis
DOI: 10.32364/2618-8430-2025-8-1-4
V.D. Kazantseva, L.A. Ozolinya, T.N. Savchenko, Yu.E. Dobrokhotova
Pirogov Russian National Research Medical University, Moscow, Russian Federation
Bacterial vaginosis (BV) represents one of the most prevalent causes of abnormal vaginal discharge with an unpleasant odor among women of reproductive age. This condition is characterized by a disruption in the vaginal microbiome, with a decline in lactobacilli dominance and an increased presence of diverse facultative and obligate anaerobic bacteria. BV has been associated with an elevated risk of adverse health outcomes, including preterm birth, ectopic pregnancy, and susceptibility to sexually transmitted infections. While the current standard of care involves the use of antibiotics, these therapies, although effective in the short term, frequently fail to address high recurrence rates. A new direction in gynecology has become the transplantation of the vaginal microbiota (TMV), which can also be considered in other conditions associated with a violation of its composition. Currently, there is an opinion that the use of lactic acid can serve as a real alternative to antibiotics and probiotics. This review aims to explore the contemporary landscape of research on non-antibiotic therapeutic approaches for BV, focusing on recent data concerning the effectiveness of alternative options such as combinations of lactic acid and glycogen, probiotics with lactobacilli, and combination treatments incorporating estriol.
Keywords: bacterial vaginosis, treatment, clindamycin, metronidazole, probiotics, prebiotics, lactic acid, glycogen.
For citation: Kazantseva V.D., Ozolinya L.A., Savchenko T.N., Dobrokhotova Yu.E. Modern treatment tactics and prophylaxis of bacterial vaginosis. Russian Journal of Woman and Child Health. 2025;8(1):27–31 (in Russ.). DOI: 10.32364/2618-8430-2025-8-1-4
ABOUT THE AUTHORS:
Valeria D. Kazantseva — Assistant Professor at the Department of Obstetrics and Gynecology at the Institute of Surgery, Pirogov Russian National Research Medical University, 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-4011-3195
Lyudmila A. Ozolinya — Dr. Sc. (Med.), Professor of the Department of Obstetrics and Gynecology at the Institute of Surgery, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-2353-123Х
Tatyana N. Savchenko — Dr. Sc. (Med.), Professor of the Department of Obstetrics and Gynecology at the Institute of Surgery, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0001-7244-4944
Yulia E. Dobrokhotova — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics and Gynecology at the Institute of Surgery, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-7830-2290
Contact information: Valeria D. Kazantseva, e-mail: shapee08@mail.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 14.02.2025.
Revised 18.02.2025.
Accepted 24.02.2025.
2. Petrova M.I., Lievens E., Malik S. et al. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol. 2015;6:81. DOI: 10.3389/fphys.2015.00081
3. Peebles K., Velloza J., Balkus J.E. et al. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019;46(5):304–311. DOI: 10.1097/OLQ.0000000000000972
4. Swidsinski A., Mendling W., Loening-Baucke V. et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013–1023. DOI: 10.1097/01.AOG.0000183594.45524.d2
5. Muzny C.A., Taylor C.M., Swords W.E. et al. An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. J Infect Dis. 2019;220(9):1399–1405. DOI: 10.1093/infdis/jiz342
6. Muzny C.A., Łaniewski P., Schwebke J.R., Herbst-Kralovetz M.M. Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Curr Opin Infect Dis. 2020;33(1):59–65. DOI: 10.1097/QCO.0000000000000620
7. Tidbury F.D., Langhart A., Weidlinger S., Stute P. Non-antibiotic treatment of bacterial vaginosis-a systematic review. Arch Gynecol Obstet. 2021;303(1):37–45. DOI: 10.1007/s00404-020-05821-x
8. Forcey D.S., Vodstrcil L.A., Hocking J.S. et al. Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review. PLoS One. 2015;10(12):e0141905. DOI: 10.1371/journal.pone.0141905
9. Schwebke J.R., Lensing S.Y., Lee J. et al. Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2021;73(3):e672–e679. DOI: 10.1093/cid/ciaa1903
10. Muzny C.A., Sobel J.D. The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment. Antibiotics (Basel). 2022;11(4):500. DOI: 10.3390/antibiotics11040500
11. Coudray M.S., Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143–148. DOI: 10.1016/j.ejogrb.2019.12.035
12. Sherrard J., Wilson J., Donders G. et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258–1272. DOI: 10.1177/0956462418785451
13. Bradshaw C.S., Morton A.N., Hocking J. et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. DOI: 10.1086/503780
14. Swidsinski A., Mendling W., Loening-Baucke V. et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1–6. DOI: 10.1016/j.ajog.2007.06.039
15. Nagaraja P. Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol. 2008;26(2):155–157. DOI: 10.4103/0255-0857.40531
16. Li T., Zhang Z., Wang F. et al. Antimicrobial Susceptibility Testing of Metronidazole and Clindamycin against Gardnerella vaginalis in Planktonic and Biofilm Formation. Can J Infect Dis Med Microbiol. 2020;2020:1361825. DOI: 10.1155/2020/1361825
17. Petrina M., Cosentino L.A., Rabe L.K., Hillier S.L. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115–119. DOI: 10.1016/j.anaerobe.2017.05.005
18. Bannatyne R.M., Smith A.M. Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis. Sex Transm Infect. 1998;74(6):455–456. PMID: 10195061
19. Beigi R.H., Austin M.N., Meyn L.A. et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2004;191(4):1124–1129. DOI: 10.1016/j.ajog.2004.05.033
20. Bostwick D.G., Woody J., Hunt C., Budd W. Antimicrobial resistance genes and modelling of treatment failure in bacterial vaginosis: clinical study of 289 symptomatic women. J Med Microbiol. 2016;65(5):377–386. DOI: 10.1099/jmm.0.000236
21. Sobel J.D., Ferris D., Schwebke J. et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194(5):1283–1289. DOI: 10.1016/j.ajog.2005.11.041
22. Workowski K.A., Bachmann L.H., Chan P.A. et al. Sexually Transmitted Infections Treatment Guidelines. MMWR Recomm Rep. 2021;70(4):1–187. DOI: 10.15585/mmwr.rr7004a1
23. Sobel J.D., Sobel R. Current and emerging pharmacotherapy for recurrent bacterial vaginosis. Expert Opin Pharmacother. 2021;22(12):1593–1600. DOI: 10.1080/14656566.2021.1904890
24. Доброхотова Ю.Э., Шадрова П.А. Терапевтические стратегии секнидазола в лечении бактериального вагиноза. РМЖ. Мать и дитя. 2022;297–302. DOI: 10.32364/2618-8430-2022-5-4-297-302Dobrokhotova Yu.E., Shadrova P.A. Therapeutic capabilities of secnidazole in the treatment of bacterial vaginosis. Russian Journal of Woman and Child Health. 2022;5(4):297–302 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-297-302
25. Sobel J.D., Kaur N., Woznicki N.A. et al. Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses. Infect Drug Resist. 2019;12:2297–2307. DOI: 10.2147/IDR.S213853
26. Surapaneni S., Akins R., Sobel J.D. Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen. Sex Transm Dis. 2021;48(10):761–765. DOI: 10.1097/OLQ.0000000000001420
27. van De Wijgert J., Verwijs M.C. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. BJOG. 2020;127(2):287–299. DOI: 10.1111/1471-0528.15870
28. Senok A.C., Verstraelen H., Temmerman M., Botta G.A. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009;(4):CD006289. DOI: 10.1002/14651858.CD006289.pub2
29. Bohbot J.M., Daraï E., Bretelle F. et al. Erratum to: "Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence" [J Gynecol Obstet Hum Reprod. 2018;47:81–87]. J Gynecol Obstet Hum Reprod. 2018;47(4):177. DOI: 10.1016/j.jogoh.2018.03.005
30. Hemmerling A., Harrison W., Schroeder A. et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010;37(12):745–750. DOI: 10.1097/OLQ.0b013e3181e50026
31. Marcone V., Rocca G., Lichtner M., Calzolari E. Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int J Gynaecol Obstet. 2010;110(3):223–226. DOI: 10.1016/j.ijgo.2010.04.025
32. Eriksson K., Carlsson B., Forsum U., Larsson P.G. A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol. 2005;85(1):42–46. DOI: 10.1080/00015550410022249
33. Cohen C.R., Wierzbicki M.R., French A.L. et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020;382(20):1906–1915. DOI: 10.1056/NEJMoa1915254
34. Donders G.G., Van Bulck B., Van De Walle P. et al. Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor®) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest. 2010;70(4):264–272. DOI: 10.1159/000314016
35. Schwebke J.R., Carter B.A., Waldbaum A.S. et al. A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis. Eur J Obstet Gynecol Reprod Biol X. 2021;10:100121. DOI: 10.1016/j.eurox.2021.100121
36. Mendling W., Holzgreve W. Astodrimer sodium and bacterial vaginosis: a mini review. Arch Gynecol Obstet. 2022;306(1):101–108. DOI: 10.1007/s00404-022-06429-z
37. Ali A., Jørgensen J.S., Lamont R.F. The contribution of bacteriophages to the aetiology and treatment of the bacterial vaginosis syndrome. Fac Rev. 2022;11:8. DOI: 10.12703/r/11-8
38. Landlinger C., Tisakova L., Oberbauer V. et al. Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo. Pathogens. 2021;10(1):54. DOI: 10.3390/pathogens10010054
39. Кира Е.Ф., Припутневич Т.В., Муравьева В.В., Халтурина Ю.В. Трансплантация вагинальной микробиоты. Акушерство и гинекология. 2023;10:39–46. DOI: 10.18565/aig.2023.142Kira E.F., Priputnevich T.V., Muravieva V.V., Khalturina Yu.V. Vaginal microbiota transplantation. Obstetrics and Gynecology. 2023;(10):39–46 (in Russ.). DOI: 10.18565/aig.2023.142
40. Wrønding T., Vomstein K., Bosma E.F. et al. Antibiotic-free vaginal microbiota transplant with donor engraftment, dysbiosis resolution and live birth after recurrent pregnancy loss: a proof of concept case study. EClinicalMedicine. 2023;61:102070. DOI: 10.1016/j.eclinm.2023.102070
41. Macklaim J.M., Clemente J.C., Knight R. et al. Changes in vaginal microbiota following antimicrobial and probiotic therapy. Microb Ecol Health Dis. 2015;26:27799. DOI: 10.3402/mehd.v26.27799
42. Petrova M.I., Macklaim J.M., Wuyts S. et al. Comparative Genomic and Phenotypic Analysis of the Vaginal Probiotic Lactobacillus rhamnosus GR-1. Front Microbiol. 2018;9:1278. DOI: 10.3389/fmicb.2018.01278
43. Onderdonk A.B., Delaney M.L., Fichorova R.N. The Human Microbiome during Bacterial Vaginosis. Clin Microbiol Rev. 2016;29(2):223–238. DOI: 10.1128/CMR.00075-15
44. Доброхотова Ю.Э., Казанцева В.Д., Озолиня Л.А., Савченко Т.Н. Терапевтические стратегии при различных фенотипических вариантах бактериального вагиноза. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2024;11:440–448. DOI: 10.17816/aog630065Dobrokhotova Yu.E., Kazantseva V.D., Ozolinya L.A., Savchenko T.N. Treatment strategies in different phenotypic forms of bacterial vaginosis. V.F. Snegirev Archives of Obstetrics and Gynecology. 2024;11:440–448 (in Russ.). DOI: 10.17816/aog630065
45. Кира Е.Ф., Коршакова Н.Ю. Открытое рандомизированное плацебо-контролируемое изучение эффективности и безопасности монотерапии бактериального вагиноза вагинальным применением молочной кислоты. Акушерство и гинекология. 2018;5:96–101. DOI: 10.18565/aig.2018.5.96-101Kira E.F., Korshakova N.Y. Open randomized placebo-con- trolled study of the effectiveness and safety of monotherapy of bacterial vaginosis by vaginal application of lactic acid. Obstetrics and gynecology. 2018;(5):96–101 (in Russ.). DOI: 10.18565/aig.2018.5.96-101
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать